Driven by leading pharmaceutical companies’ performance and the easing of tensions in the Middle East, the largest Hang Seng Pharma ETF Huaxia (159892) rose by 1.77%, while the HK Connect Healthcare ETF Huaxia (520510) garnered significant investor attent
Gelonghui, March 26 | Today, the healthcare sector of Hong Kong stocks rebounded. The HShares Healthcare ETF (159892) managed by China Asset Management rose by 1.7%, with a turnover of 474 million yuan. The H-Shares Medical ETF (520510) managed by China Asset Management increased by 1.64%. Over the past 10 trading days, it saw net inflows on 7 days, totaling 21.48 million yuan. Trading activity has significantly improved compared to previous levels, reflecting renewed investor sentiment toward the innovative drug sector in Hong Kong stocks. The strengthening of the pharmaceuticals sector today was primarily driven by the following news:
① Eased tensions in the Middle East have boosted risk appetite, driving capital flows from safe-haven assets to growth sectors such as pharmaceuticals.
② Leading companies reported better-than-expected earnings. Wuxi Apptec’s 2025 annual report exceeded expectations, with total revenue reaching 45.456 billion yuan, up 15.8% year-over-year. Net profit attributable to shareholders reached 19.151 billion yuan, a substantial increase of 102.7% year-over-year. The company forecasts that its total revenue in 2026 will reach between 51.3 billion and 53 billion yuan. Beigene turned profitable in 2025, with net profit reaching 1.42 billion yuan. Its revenue guidance for 2026 is set between 43.6 billion and 45 billion yuan, indicating significantly enhanced profitability.
③ Unprecedented elevation in industrial policy positioning: The 2026 government work report, for the first time, designated biomedicine as an “emerging pillar industry,” placing it alongside integrated circuits and aerospace, marking a historic leap in strategic importance. Guosheng Securities noted that the upgrade in biomedicine policy positioning will benefit innovative drugs as a core high-value-added segment, recommending attention to the innovative drug supply chain and brain-computer interface themes. CITIC Securities emphasized that the acceleration of overseas expansion for innovative drugs benefits the CXO sector through order recovery and capacity expansion, with sustained upward momentum in the industry’s outlook.
Related products: A representative of the global pharmaceuticals industry chain: HShares Healthcare ETF (159892), with the latest scale of 5.896 billion yuan, is the largest among similar products. Its top ten weighted stocks include Beigene, Wuxi Bio, Akeso, Sino Biopharm, and 3SBio.
Deep focus on CXO and AI healthcare: H-Shares Medical ETF (520510), with CXO accounting for over 30% of its weight, ranks among the highest in the market. Weighted stocks include Wuxi Bio (leader in CDMO): (a global frontrunner in bispecific antibody R&D), MicroPort CardioFlow Medtech Corporation (pioneer in domestic substitution within cardiovascular intervention), JD Health (leader in medical digitalization).
